(OC-6-43)-dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV) | 500111-51-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (OC-6-43)-dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV)
• 英文别名: N',N'-dimethylethane-1,2-diamine;platinum(4+);dichloride;dihydroxide
• CAS: 500111-51-3
• 化学式: C₄H₁₄Cl₂N₂O₂Pt
• 分子量: 388.153
• InChiKey: KJNCGZOIJYHXKK-UHFFFAOYSA-J

计算性质

• 辛醇/水分配系数(LogP)：
  -6.84
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  31.3
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  异氰酸丙酯 、 (OC-6-43)-dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV) 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 以42%的产率得到(OC-6-54)-dichlorido(N,N-dimethylethane-1,2-diamine)-hydroxidopropylcarbamatoplatinum(IV)
  参考文献：
  名称：

  Bulky N(,N)-(Di)alkylethane-1,2-diamineplatinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes

  摘要：

  Investigations of the influence of bulky groups in the equatorial ligand sphere of platinum(IV) compounds on the complexes' stability and reaction pattern were performed. Four dihydroxidoplatinum(IV) complexes were reacted with anhydrides, cinnamoyl chloride, and n-propyl isocyanate and yielded the symmetric dicarboxylated products or, if steric hindrance was observed, unsymmetrically substituted monocarboxylated analogues. With the aim of raising the steric demand, the following ligands were chosen: N-cycloheitylethane-1,2-diamine, N,N-dimethylethane-1,2-diamine, N,N-diethylethane-1,2-diamine, and N,N-diisopropylethane-1,2-diamine. All of the novel complexes were characterized by electrospray ionization mass spectrometry (ESI-MS), one- and two-dimensional NMR spectroscopy, elemental analysis, and reversed-phase HPLC; complexes B3, C3, C6, and D4 were also analyzed by X-ray diffraction. Additionally, the cytotoxicities of 10 compounds toward the cisplatin-sensitive cell line CH1 and the intrinsically cisplatin-resistant cell lines A549 and SW480 were investigated, and IC50 values down to the nanomolar range were found. To aid in the interpretation of structure-activity relationships, log k(w) values as a measure for the lipophilicity were determined for all of the new complexes, and the rates of reduction of C1, C3, and C4 relative to satraplatin were determined by means of NMR spectroscopy and ESI-MS.

  DOI：

  10.1021/ic400816g
• 作为产物：
  描述：

  (SP-4-3)-dichlorido(N,N-dimethylethane-1,2-diamine)platinum(II) 、 双氧水 以 水 为溶剂， 以96%的产率得到(OC-6-43)-dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV)
  参考文献：
  名称：

  Mono-carboxylated diaminedichloridoplatinum(iv) complexes – selective synthesis, characterization, and cytotoxicity

  摘要：

  通过琥珀酸酐对（OC-6-43）-二氯（N，N-二甲基乙二胺）二羟基铂（IV）进行选择性单羧化，然后进行酯化反应，得到了新的细胞毒性铂配合物，其IC50值降至低纳摩尔范围。

  DOI：

  10.1039/c1dt10301f

文献信息

• Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes
  作者：Helena Henke、Kushtrim Kryeziu、Jelena Banfić、Sarah Theiner、Wilfried Körner、Oliver Brüggemann、Walter Berger、Bernhard K. Keppler、Petra Heffeter、Ian Teasdale

  DOI：10.1002/mabi.201600035

  日期：2016.8

  The preparation of novel macromolecular prodrugs via the conjugation of two platinum(IV) complexes to suitably functionalized poly(organo)phosphazenes is presented. The inorganic/organic polymers provide carriers with controlled dimensions due to the use of living cationic polymerization and allow the preparation of conjugates with excellent aqueous solubility but long‐term hydrolytic degradability

  介绍了通过将两个铂 (IV) 配合物与适当官能化的聚 (有机) 磷腈共轭制备新型大分子前药。由于使用活性阳离子聚合，无机/有机聚合物为载体提供了可控尺寸，并允许制备具有优异水溶性但长期水解降解性的缀合物。大分子 Pt(IV) 前药被设计为经历细胞内还原并同时从大分子载体释放以呈现活性 Pt(II) 药物衍生物。体外研究表明，与小分子 Pt 复合物相比，大分子前药对 Pt 的细胞内摄取显着增强，这也反映在细胞毒性的增加上。有趣的是，与临床上建立的铂类药物相比，耐药亚系对偶联物的耐药性也显着降低，这表明 Pt(IV) 偶联物​​的替代摄取途径也可能能够克服对 Pt(II) 药物的获得性耐药性。与相应的 Pt(IV) 复合物相比，选定的偶联物的体内研究表明肿瘤缩小有所改善。